Effects of an angiotensin-converting enzyme inhibitor and a β-blocker on cerebral arterioles in rats

被引:51
|
作者
Chillon, JM
Baumbach, GL
机构
[1] Univ Iowa, Coll Med, Dept Pathol, Med Labs 100, Iowa City, IA 52242 USA
[2] Univ Iowa, Ctr Cardiovasc, Iowa City, IA 52242 USA
关键词
hypertension; chronic; vascular remodeling; angiotensin; hypertrophy; vascular;
D O I
10.1161/01.HYP.33.3.856
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
We examined the effects of an angiotensin-converting enzyme inhibitor, perindopril, and a beta-blocker, propranolol, on cerebral arterioles in stroke-prone spontaneously hypertensive rats (SHRSP). The structure and mechanics of cerebral arterioles were examined in untreated Wistar-Kyoto rats (WKY) and SHRSP that were untreated or treated for 3 months with a high (2 mg/kg per day) or a low (0.3 mg/kg per day) dose of perindopril or propranolol (250 mg/kg per day) alone or in combination with the low dose of perindopril. We measured pressure, external diameter, and cross-sectional area of the vessel wall (CSA) in maximally dilated (with EDTA) cerebral arterioles. Treatment of SHRSP with the high dose of perindopril or the combination of propranolol and the low dose of perindopril normalized cerebral arteriolar mean pressure (50+/-1 [mean+/-SEM] and 43+/-2 mm Hg vs 50+/-1 mm Hg in WKY and 94+/-3 mm Hg in untreated SHRSP; P<0.05), pulse pressure (15+/-1 and 16+/-1 mm Hg vs 13+/-1 mm Hg in WKY and 35+/-1 mm Hg in untreated SHRSP; P<0.05), and CSA (1103+/-53 and 1099+/-51 mu m(2), respectively, vs 1057+/-49 mu m(2) in WKY and 1281+/-67 mu m(2) in untreated SHRSP; P<0.05). In contrast, treatment of SHRSP with the law dose of perindopril or propranolol alone did not normalize arteriolar pulse pressure (24+/-1 and 21+/-1 mm Hg) and failed to prevent increases in CSA (1282+/-77 and 1267+/-93 mu m(2)). Treatment with either dose of perindopril or the combination of propranolol and perindopril significantly increased external diameter in cerebral arterioles of SHRSP (99+/-3, 103+/-2, and 98+/-3 mu m vs 87+/-2 mu m in untreated SHRSP; P<0.05), whereas propranolol alone did not (91+/-3 mu m; P>0.05). These findings suggest that effects of angiotensin-converting enzyme inhibitors on cerebral arteriolar hypertrophy in SHRSP map depend primarily on their effects on arterial pressure, particularly pulse pressure, whereas their effects on cerebral arteriolar remodeling (defined as a reduction in external diameter) may be pressure independent.
引用
收藏
页码:856 / 861
页数:6
相关论文
共 50 条
  • [41] Effects of Angiotensin-Converting Enzyme Inhibitory Peptide LAP on Vascular Remodeling
    Huang, Junling
    Luo, Ming
    Fang, Hong
    Zheng, Huan
    Shen, Yi
    Li, Lingxia
    Deng, Yuqing
    Xu, Huifeng
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2013, 35 (06) : 437 - 443
  • [42] Value of Pleiotropic Effects of Angiotensin-Converting Enzyme Inhibitors
    Zagidullin, N. Sh.
    Valeeva, K. F.
    Gassanov, F.
    Zagidullin, Sh. Z.
    KARDIOLOGIYA, 2010, 50 (11) : 55 - 60
  • [43] Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Use and COVID-19: Time to Change Practice or Keep Gathering Data?
    de Feria, Alejandro
    Ortega-Legaspi, Juan M.
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (09) : 2457 - 2458
  • [44] Angiotensin-converting enzyme gene polymorphism and plasminogen activator inhibitor 1 levels in subjects with cerebral infarction
    Seino, Y
    Ikeda, U
    Maeda, Y
    Haga, Y
    Yashima, H
    Shimada, K
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 1998, 5 (03) : 263 - 267
  • [45] ANGIOTENSIN-CONVERTING ENZYME-INHIBITION AND VASCULAR STRUCTURE IN HYPERTENSION
    GIBBONS, GH
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1991, 18 : S19 - S24
  • [46] A comparative study of morphological changes in spontaneously hypertensive rats and normotensive Wistar Kyoto rats treated with an angiotensin-converting enzyme inhibitor or a calcium-channel blocker
    Saleh, FH
    Jurjus, AR
    JOURNAL OF PATHOLOGY, 2001, 193 (03) : 415 - 420
  • [47] Angiotensin-Converting Enzyme Gene Polymorphism and Plasminogen Activator Inhibitor 1 Levels in Subjects with Cerebral Infarction
    Yoshitane Seino
    Uichi Ikeda
    Yoshikazu Maeda
    Yasushi Haga
    Harumitsu Yashima
    Kazuyuki Shimada
    Journal of Thrombosis and Thrombolysis, 1998, 5 : 263 - 267
  • [48] Late-onset angioedema due to an angiotensin-converting enzyme inhibitor
    Garcia-Pavia, Pablo
    Tomas, Jose M.
    Alonso-Pulpon, Luis
    CANADIAN JOURNAL OF CARDIOLOGY, 2007, 23 (04) : 315 - 316
  • [49] Principles of choice of an angiotensin-converting enzyme inhibitor: Specific features of perindopril
    Morozova, T. E.
    Gontarenko, S. V.
    Kuzmina, E. R.
    TERAPEVTICHESKII ARKHIV, 2014, 86 (09) : 115 - +
  • [50] RENAL RESPONSES TO ANGIOTENSIN RECEPTOR ANTAGONIST AND ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR IN PARTIALLY NEPHRECTOMIZED SPONTANEOUSLY HYPERTENSIVE RATS
    OKADA, H
    SUZUKI, H
    KANNO, Y
    IKENAGA, H
    SARUTA, T
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1995, 26 (04) : 564 - 569